The Chicago Declaration: HPV Vaccine Safety

unnamedOn May 27, 2016, representatives from several nations convened in Chicago, Illinois, USA, for the first international symposium on human papillomavirus (HPV) vaccine safety. These representatives observed an alarming pattern of harm[1] after HPV vaccine administration in every nation where they have been distributed. We observed glaring evidence of conflicts of interest among government regulators and improper collusion between government regulators and the pharmaceutical/vaccine industry in every nation where HPV vaccines have been used. The global pattern manifests in the suppression of information implicating HPV vaccinations of potential harm, including suppression of efforts by medical researchers to investigate adverse events.

The global denial of harm and subsequent pattern of regulatory failures have obstructed efforts to properly diagnose and treat the injured, exponentially increasing the harm to children and adults.

These situations are exacerbated because vaccines are the only medical products which currently:

  • Do not have to prove effectiveness as a condition of market approval.
  • Are tested for safety, not against an inert saline placebo, but against other vaccines, or vaccine adjuvants making it impossible to accurately assess safety.
  • Vaccine manufacturers in many countries enjoy protection from liability, even for design or manufacturing defects.

Consequently, the international events outlined above require a global response from all who are concerned about HPV vaccine safety.

On May 26, 2016 the Nordic Cochrane Centre issued a Complaint to the European Medicines Agency (EMA) over maladministration at the EMA. The Cochrane Centre complaint confirms observations put forth by a multitude of HPV vaccine safety groups. Those who attended the international HPV vaccine safety symposium and others throughout the world completely agree with and support investigations into the ten critical issues raised in the Cochrane complaint. However, we question the ability of any agency to investigate their own actions objectively and/or propose any meaningful solutions to problems discovered.

Therefore, the Global Health Coalition calls on every nations’ elected officials to protect the public health and safety by establishing the following:

  • Independent Committees to investigate the allegations put forth by the Nordic Cochrane Centre in their letter of complaint to the EMA. Any malfeasance discovered should be dealt with immediately and to the fullest extent allowed by law.
  • Medical teams composed of individuals with no ties to the pharmaceutical industry to examine all adverse events reported after HPV vaccine administration. These teams should be responsible for determining whether or not HPV vaccines are causally associated with the adverse events and if so, which individuals are most susceptible to adverse reactions and why. They should also be responsible for organizing interdisciplinary teams to establish effective treatment protocols for the injured.
  • Task forces completely independent of pharmaceutical influence to examine current national health policies to determine what changes need to be implemented to prevent this type of public health disaster from happening in the future.

The Global Health Coalition, the undersigned organizations and individuals believe the first priority of any government is to protect the health and safety of their citizens. If the health agencies sponsored by their respective governments to handle this task fail to handle their responsibilities, elected officials must step in and remedy the situation.

There is no greater endeavor than protecting children and young adults from unnecessary harm due to any medical intervention.

Signed by,

Robert Krakow, Attorney and Founder of the Global Health Coalition


[1] Following HPV vaccine administration, there have been consistent global reports of the following: headaches, diagnoses of autoimmune and/or dysautonomia conditions such as postural orthostatic tachycardia syndrome (“POTS”), and including, but not limited to all conditions listed in the current package inserts